CERo Therapeutics Secures $11.7M Senior Secured Financing, Pledges All Subsidiary Assets Including CER-1236 IP
CEROW sits 55% above its 52-week low of $0.001.
Summary
CERo Therapeutics consolidated $5.67M of prior debt into a new senior secured note with a $6M additional advance facility, pledging all subsidiary assets and equity as collateral. The note matures October 15, 2026.
Key Events · Financing and Capital Events · CEROW
-
Senior Secured Note Consolidates Prior Debt
Consolidated $5,666,108.77 of prior unsecured convertible notes into a new senior secured promissory note with SRX Global Inc., replacing all previous conversion terms.
-
$6M Additional Advance Facility
Note provides up to $6,000,000 in additional advances (total max $11,666,108.77), with an initial $775,665 advance funded on August 27, 2026 after withholding $50,000 for legal fees.
-
All Subsidiary Assets Pledged as Collateral
First-priority security interest granted over substantially all subsidiary assets including CER-1236 patents, clinical trials, and regulatory applications, plus 100% of subsidiary equity.
-
Maturity Date October 15, 2026
Note matures October 15, 2026 with up to four 30-day extensions at lender's discretion; 10% interest rate rising to 24.99% on default.
Analysis · CEROW · Life Sciences
CERo Therapeutics has converted $5.67 million of unsecured convertible notes into a senior secured obligation and added a $6 million advance facility, with the lender taking a first-priority security interest in substantially all subsidiary assets — including the CER-1236 cell therapy patents and clinical data. The initial $775,665 advance was funded immediately, but the note matures on October 15, 2026, giving the company less than seven weeks to repay or renegotiate. The pledge of 100% of subsidiary equity and all intellectual property means a default could strip the company of its core therapeutic assets. For a company with a market cap under $1 million, this is a survival financing with severe collateral consequences.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CEROW was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $757.1K. The 52-week trading range was $0.00 to $0.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.